Human error is common in forex trading and often leads to familiar trading issues. These trading mishaps lead to significant novice traders regularly. …
At historically low interest rates, refinancing can seem tempting; but applications for refinance could be denied for various reasons. Underwriters need assurances that…
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights.
Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Biogen Company is mentioned.
We assess its relevance and importance to carry out an overall sentiment valuation of Biogen Inc. (BIIB).
You can view the trend designation for each individual article below.
We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Biogen stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 19.57% and 6.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend:Neutral
March 28, 2024 (12:00) / "Investors Business Daily" (by ALLISON GATLIN)
Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.
In Article Trend:Somewhat-Bullish
March 25, 2024 (11:30) / "Benzinga" (by Globe Newswire)
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
In Article Trend:Somewhat-Bullish
March 25, 2024 (11:18) / "PR Newswire" (by Bio-Thera Solutions)
Biogen Inc BIIB and Eisai Co Ltd ESALF ESALY faced a setback as the much-anticipated Oral Explanation slated for March 19 at the Committee for Medicinal Products for Human Use ( CHMP ) was postponed.
In Article Trend:Neutral
March 19, 2024 (11:01) / "Canada Newswire" (by Biogen Canada)
• SOD1- ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS that represents approximately two percent of all ALS cases1 • Health regulatory decision on tofersen New Drug Submission expected in early 2025
Investors with a lot of money to spend have taken a bullish stance on Biogen BIIB. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
GUANGZHOU, China and SAN JOSÉ, Costa Rica, March 18, 2024 /PRNewswire/ -- Bio-Thera Solutions, a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, and SteinCares, one of Latin America's leading specialty healthcare companies, announced today a new ...
LEXINGTON, Mass., March 13, 2024 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. VYGR, a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer ( CMO ) , effective March 25, 2024.
In Article Trend:Neutral
March 13, 2024 (11:00) / "GlobeNewswire" (by Voyager Therapeutics)
LEXINGTON, Mass., March 13, 2024 ( GLOBE NEWSWIRE ) -- Voyager Therapeutics, Inc. ( Nasdaq: VYGR ) , a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer ( CMO ) , effective March 25, 2024.
LONDON, March 12, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Proliferative Diabetic Retinopathy ( PDR ) Global Market Report 2024, the proliferative diabetic retinopathy ( PDR ) market has experienced significant growth in recent years, with the proliferative diabetic ...
In Article Trend:Somewhat-Bullish
March 12, 2024 (12:32) / "Zacks Commentary" (by Aparajita Dutta)
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy FRPT, ATR, MFC, HWKN and COLD.
The FDA has delayed a decision on whether it will approve donanemab, Eli Lilly's closely watched new Alzheimer's drug, despite promising study results that showed it could significantly slow cognitive and functional decline in early-symptomatic Alzheimer's patients, the pharmaceutical company ...
In Article Trend:Neutral
March 8, 2024 (15:08) / "Investors Business Daily" (by ALLISON GATLIN)
The Food and Drug Administration has delayed a decision on Eli Lilly ( LLY ) Alzheimer's drug donanemab, the company said Friday. Eli Lilly stock edged lower. Biogen ( BIIB ) rose. The FDA now wants to convene an advisory panel for the Lilly drug, but there's no date set yet.
Drugmaker Eli Lilly says that approval of its experimental Alzheimer's medication donanemab will be delayed beyond the end of March as the US Food and Drug Administration plans to call a last-minute meeting of its outside advisers to review the drug's safety and efficacy.
In Article Trend:Neutral
March 7, 2024 (20:19) / "Benzinga" (by Globe Newswire)
NEW YORK, March 07, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ( "Biogen" or the "Company" ) BIIB. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend:Neutral
March 7, 2024 (05:46) / "Benzinga" (by PRNewswire)
STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's ( publ ) BIOA ( Stockholm: BIOA B ) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi, the world's first fully approved disease-modifying treatment for Alzheimer's disease.
New data from the RESPOND study show that neurofilament levels, an indicator of neurodegeneration, were reduced in nearly all study participants treated with SPINRAZA Reductions in biomarker complement previously reported RESPOND efficacy results showing improved motor function in most ...
In Article Trend:Neutral
March 6, 2024 (12:30) / "GlobeNewswire" (by Biogen Inc.)
CAMBRIDGE, Mass., March 06, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year ...
New data advances understanding of new approaches to treating Alzheimer's disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc.
In Article Trend:Neutral
March 4, 2024 (21:15) / "GlobeNewswire" (by Biogen Inc.)
CAMBRIDGE, Mass., March 04, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced it will present new data from its Alzheimer's disease ( AD ) portfolio at the upcoming International Conference on Alzheimer's and Parkinson's Diseases ( AD/PD™ 2024 ) , taking place March 5-9 in ...
In Article Trend:Neutral
March 4, 2024 (03:37) / "The Financial Express" (by Health Desk)
Biogen's stance at the upcoming AD/PD 2024 International Conference on Alzheimer's disease ( AD ) and Parkinson's disease ( PD ) that will be held on March 5-9 will demonstrate its future plans for AD following the discontinuation of Aduhelm ( aducanumab ) , its anti-amyloid beta ( Aβ ) ...
In Article Trend:Neutral
March 3, 2024 (15:15) / "PR Newswire" (by Pomerantz LLP)
NEW YORK, March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ( "Biogen" or the "Company" ) ( NASDAQ: BIIB ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend:Neutral
March 2, 2024 (09:53) / "Motley Fool" (by Alex Carchidi)
Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Denali Therapeutics Inc. ( Nasdaq: DNLI ) , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ( BBB ) for the treatment of neurodegenerative diseases and ...
In Article Trend:Somewhat-Bullish
February 24, 2024 (07:30) / "Benzinga" (by Globe Newswire)
NEW YORK, Feb. 24, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Biogen Inc. ( "Biogen" or the "Company" ) BIIB on behalf of Biogen stockholders.
In Article Trend:Neutral
February 23, 2024 (12:00) / "Benzinga" (by Globe Newswire)
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1 With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field
In Article Trend:Neutral
February 23, 2024 (12:00) / "GlobeNewswire" (by Biogen Inc.)
CAMBRIDGE, Mass., Feb. 23, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) adopted a positive opinion recommending a marketing authorization under exceptional circumstances for ...
In Article Trend:Neutral
February 22, 2024 (20:04) / "Benzinga" (by Globe Newswire)
EXTON, PA, Feb. 22, 2024 ( GLOBE NEWSWIRE ) -- The 2023 announcement of newly approved disease-modifying therapy ( DMT ) Leqembi ( lecanemab ) for Alzheimer's Disease ( AD ) sparked eager anticipation within both the medical community and among families nationwide.
Biogen ( NASDAQ:BIIB - Get Free Report ) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday.
In Article Trend:Somewhat-Bullish
February 19, 2024 (20:30) / "Benzinga" (by Benzinga Insights)
Biogen's BIIB short percent of float has fallen 18.77% since its last report. The company recently reported that it has 3.06 million shares sold short, which is 2.38% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.22 days to cover their ...
The industrial sector, which includes manufacturing, construction, and more, has a solid footing, with several factors such as technological innovation, sustained consumer demand for industrial products and services, growing investments in infrastructure, and favorable government funding and ...
In Article Trend:Somewhat-Bullish
February 17, 2024 (13:49) / "CNBC" (by Kenneth Squire)
FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.
Tuesday, Biogen Inc BIIB posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency ( CC ) . Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for CrowdStrike Holdings, Inc. CRWD from $318 to $375.
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report. The Consumer Price Index ( CPI ) rose at a 3.1% annual rate in January, down from December's 3.4% ...
In Article Trend:Neutral
February 13, 2024 (17:42) / "Benzinga" (by Vandana Singh)
On Tuesday, Biogen Inc BIIB posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency ( CC ) . Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18. Multiple sclerosis revenue of $1.17 billion decreased by 8% ...
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.
In Article Trend:Somewhat-Bullish
February 13, 2024 (13:46) / "Investors Business Daily" (by ALLISON GATLIN)
Biogen ( BIIB ) stock slumped early Tuesday after the biotech company reported adjusted earnings of $2.95 per share on $2.39 billion in fourth-quarter sales. On average, analysts polled by FactSet expected Biogen to earn $3.18 per share on $2.47 billion in sales.
Biogen Inc. (BIIB) delivered earnings and revenue surprises of -6.65% and 2.88%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend:Neutral
February 13, 2024 (12:21) / "MarketWatch" (by Eleanor Laise)
Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining multiple-sclerosis product sales.
In Article Trend:Neutral
February 13, 2024 (12:03) / "CNBC" (by Annika Kim Constantino)
Wall Street is poised to open in the red on Tuesday as stock futures declined ahead of the all-important consumer price inflation report for January. Overbought levels could be on traders' minds, especially as the market moves past the crucial phase of the reporting season.
In Article Trend:Neutral
February 13, 2024 (09:26) / "Stocknews.com" (by Defense World Staff)
StockNews.com upgraded shares of Biogen ( NASDAQ:BIIB - Free Report ) from a hold rating to a buy rating in a research report sent to investors on Monday morning.
In Article Trend:Somewhat-Bullish
February 12, 2024 (21:06) / "Benzinga" (by Globe Newswire)
Friedreich's ataxia is a rare, genetic, life-shortening, debilitating, and neurodegenerative disorder Treatment with SKYCLARYS improved patient function compared to placebo Biogen is leveraging its expertise and capabilities in rare disease to bring this groundbreaking treatment to patients
In Article Trend:Neutral
February 12, 2024 (21:06) / "GlobeNewswire" (by Biogen Inc.)
CAMBRIDGE, Mass., Feb. 12, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) announced the European Commission ( EC ) has authorized SKYCLARYS® ( omaveloxolone ) for the treatment of Friedreich's ataxia ( FA ) in adults and adolescents aged 16 years and older.
In Article Trend:Somewhat-Bullish
February 12, 2024 (20:16) / "Benzinga" (by Benzinga Insights)
High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Biogen Inc. ( BIIB ) is set to announce its fiscal 2023 fourth-quarter earnings on February 13. Analysts predict a 3.2% year-over-year revenue dip to $2.46 billion, alongside a 21.5% decrease in EPS to $3.18 for the quarter. Nonetheless, the company is undertaking initiatives to expand its growth ...
In order to turn $50,000 into $1 million by investing, you have to find stocks that the Street is underestimating. Of course, to achieve that tremendous feat, investors also have to choose companies that can grow tremendously by exploiting strong trends.
In Article Trend:Somewhat-Bullish
February 9, 2024 (22:30) / "Investors Business Daily" (by Investor's Business Daily)
As the Nasdaq and S&P 500 added yet another week to their phenomenal runs, the Dow flattened out just below 39,000. The coming week sees earnings reports from Dow Jones stocks Coca-Cola ( KO ) and Cisco Systems ( CSCO ) , as well as Deere ( DE ) and Occidental Petroleum ( OXY ) .
In Article Trend:Neutral
February 9, 2024 (19:30) / "Benzinga" (by Benzinga Insights)
Biogen BIIB has outperformed the market over the past 20 years by 1.7% on an annualized basis producing an average annual return of 9.28%. Currently, Biogen has a market capitalization of $34.73 billion.
The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
In Article Trend:Neutral
February 8, 2024 (11:00) / "GlobeNewswire" (by Zymeworks Inc.)
VANCOUVER, British Columbia, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the ...
In Article Trend:Somewhat-Bullish
February 8, 2024 (11:00) / "Benzinga" (by Globe Newswire)
VANCOUVER, British Columbia, Feb. 08, 2024 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ZYME, a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of ...
In Article Trend:Somewhat-Bullish
February 7, 2024 (14:27) / "PR Newswire" (by NeuroSense)
CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. ( Nasdaq: NRSN ) ( "NeuroSense" ) , a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ( "Nasdaq" ) informing the Company ...
Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend:Somewhat-Bullish
February 5, 2024 (12:00) / "GlobeNewswire" (by Lexeo Therapeutics)
NEW YORK, Feb. 05, 2024 ( GLOBE NEWSWIRE ) -- Lexeo Therapeutics, Inc. ( Nasdaq: LXEO ) , a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced new executive ...
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
In Article Trend:Neutral
February 1, 2024 (15:00) / "Forbes" (by Katie Jennings)
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. here were a whopping two healthtech startups that hit billion-dollar valuations in 2023, compared to 52 unicorns minted during the two years prior, according to a PitchBook analysis.
Biogen Inc BIIB is pulling the plug on its Aduhelm Alzheimer's disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval.
In Article Trend:Neutral
January 31, 2024 (16:43) / "CNBC" (by Annika Kim Constantino)
Biogen is halting the development and commercialization of the Alzheimer's drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to concerns about whether its benefits outweighed its risks.
In Article Trend:Neutral
January 31, 2024 (12:30) / "GlobeNewswire" (by Biogen Inc.)
CAMBRIDGE, Mass., Jan. 31, 2024 ( GLOBE NEWSWIRE ) -- Biogen Inc. ( Nasdaq: BIIB ) today announced plans to reprioritize its resources in Alzheimer's disease ( AD ) , a strategic therapeutic area expected to drive near and long-term growth.
In Article Trend:Somewhat-Bullish
January 31, 2024 (11:00) / "Forbes" (by Kal Patel M.D.)
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat adults with highly active relapsing remitting multiple sclerosis ( RRMS ) Launch strengthens well-established Sandoz biosimilar ...
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend:Somewhat-Bullish
January 29, 2024 (13:30) / "Benzinga" (by Meg Flippin)
Amyotrophic lateral sclerosis ( ALS ) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and ultimately death within two to five years from diagnosis.
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and,
moreover, are not trading signals.
When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market
as a result of using the information contained on the site.
This website uses cookies to ensure you get the best experience on our website